0
Boehringer Ingelheim, a global leader in animal health, partnered with Henke-Sass, Wolf to develop an innovative intramuscular needle free vaccine injection tool for pigs around weaning until the end of nursery.
This novel device will be available from December 2020 to swine producers in most countries globally under two different brands FreVAX™ (through Boehringer Ingelheim) and EPIG® (through Henke-Sass, Wolf).
Stephan Lange, Head of Swine, Boehringer Ingelheim Animal Health, shares: “Both FreVAX™ and EPIG® fulfill the desire of swine producers to ensure safety of pigs and people as well as efficacy of vaccine application by avoiding broken needles and reducing pathogen transmission while increasing vaccination compliance, animal well-being and data availability and management. Our customers will truly benefit from this innovation.”
“Combining the technical skills and experience of a leading health technology company with the expertise of the global leader in swine vaccines have led to the development of a state-of-the-art innovative device addressing farmers’ needs for safe and efficacious vaccine administration,” comments Stefan Knefel, Vice President Sales & Marketing Veterinary Products, Henke-Sass, Wolf.
FreVAX™ and EPIG® replace conventional needle vaccination, ensuring smooth and painless intramuscular injections of 1 or 2 ml with no recoil, low noise level and direct feedback for the user through intelligent sensors and LED alerts. These features have been incorporated to improve the vaccination experience for both the pig and the operator whilst offering vaccination compliance and reliability. In addition, the product also provides smart functions for data capture and transfer.
All this information as well as evaluation of vaccination quality can be accessed on smart phones thanks to a specifically designed app available for download from the Apple Store and Google Play Store.
October 27, 2020 - Boehringer Ingelheim
